These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10471147

  • 1. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe.
    Schneider TJ, Struijk PC, Wallenburg HC.
    Eur J Obstet Gynecol Reprod Biol; 1999 Sep; 86(1):83-7. PubMed ID: 10471147
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys.
    Keith JC, Goodrich JA, Endo Y, Taub D, Mehlman P, Ward G.
    Prostaglandins; 1993 Jun; 45(6):547-55. PubMed ID: 8337414
    [Abstract] [Full Text] [Related]

  • 5. Lack of effect of melatonin on myometrial electromyographic activity in the pregnant sheep at 138-142 days gestation (term = 147 days gestation).
    Sadowsky DW, Yellon S, Mitchell MD, Nathanielsz PW.
    Endocrinology; 1991 Apr; 128(4):1812-8. PubMed ID: 1900777
    [Abstract] [Full Text] [Related]

  • 6. Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor.
    Cardin JP, Ross MG, Ervin MG, Schaffer AV, Douglas FL, Simke JP.
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1345-9. PubMed ID: 2220946
    [Abstract] [Full Text] [Related]

  • 7. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F.
    Thromb Haemost; 1992 Aug 03; 68(2):214-20. PubMed ID: 1412169
    [Abstract] [Full Text] [Related]

  • 8. Prostaglandin production in the umbilical and uterine circulations in pregnant sheep at 129-136 days gestation.
    Kelleman A, Binienda Z, Ding XY, Rittenhouse L, Mitchell M, Nathanielsz PW.
    J Dev Physiol; 1992 Feb 03; 17(2):63-7. PubMed ID: 1500635
    [Abstract] [Full Text] [Related]

  • 9. Effect of fetal and maternal intravascular antipyrine infusion on maternal plasma prostaglandin concentrations in the pregnant sheep at 104 to 127 days' gestation.
    Pimentel G, Figueroa JP, Mitchell MD, Massmann A, Nathanielsz PW.
    Am J Obstet Gynecol; 1986 Dec 03; 155(6):1181-5. PubMed ID: 3789031
    [Abstract] [Full Text] [Related]

  • 10. Prostanoid concentrations in maternal/fetal plasma and amniotic fluid and intrauterine tissue prostanoid output in relation to myometrial contractility during the onset of adrenocorticotropin-induced preterm labor in sheep.
    Olson DM, Lye SJ, Skinner K, Challis JR.
    Endocrinology; 1985 Jan 03; 116(1):389-97. PubMed ID: 3855257
    [Abstract] [Full Text] [Related]

  • 11. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
    Di Perri T, Notari M, Assogna G.
    Recenti Prog Med; 1991 Oct 03; 82(10):533-40. PubMed ID: 1759039
    [Abstract] [Full Text] [Related]

  • 12. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G, Hermans C, Somers Y, Van de Werf F, de Clerck F.
    J Am Coll Cardiol; 1993 Apr 03; 21(5):1269-79. PubMed ID: 8459087
    [Abstract] [Full Text] [Related]

  • 13. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
    Vanden Bossche H, Willemsens G, Bellens D, Janssen PA.
    Biochem Pharmacol; 1992 Feb 18; 43(4):739-44. PubMed ID: 1540227
    [Abstract] [Full Text] [Related]

  • 14. Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations.
    Weber C, Beetens JR, Van de Wiele R, Höller M, De Clerck F.
    Blood Coagul Fibrinolysis; 1991 Feb 18; 2(1):7-15. PubMed ID: 1773000
    [Abstract] [Full Text] [Related]

  • 15. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
    Casellas F, Papo M, Guarner F, Antolín M, Segura RM, Armengol JR, Malagelada JR.
    Eur J Gastroenterol Hepatol; 1995 Mar 18; 7(3):221-6. PubMed ID: 7743303
    [Abstract] [Full Text] [Related]

  • 16. Nitric oxide modulates placental prostanoid production from late pregnant non-insulin-dependent diabetic rat.
    González E, Jawerbaum A, Novaro V, Sinner D, Gimeno M.
    Prostaglandins Leukot Essent Fatty Acids; 1998 Nov 18; 59(5):299-304. PubMed ID: 9888203
    [Abstract] [Full Text] [Related]

  • 17. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermylen J.
    Thromb Haemost; 1990 Aug 13; 64(1):87-90. PubMed ID: 2148849
    [Abstract] [Full Text] [Related]

  • 18. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
    Naran NH, Chetty N.
    Thromb Res; 1997 Dec 01; 88(5):399-407. PubMed ID: 9556227
    [Abstract] [Full Text] [Related]

  • 19. Ridogrel. R 68070.
    Drugs R D; 1999 Mar 01; 1(3):270-2. PubMed ID: 10566044
    [No Abstract] [Full Text] [Related]

  • 20. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM, Barrow SE, Doktor HS, Stratton PD, Edwards JS, Henry JA, Gould S.
    Hypertension; 1993 Aug 01; 22(2):197-203. PubMed ID: 8340155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.